 Shares of telehealth platform and direct-to-consumer (D2C) personal care products provider Hims & Hers Health (NYSE: HIMS) fell 6.7% on Wednesday,... ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ |
Good MorningU.S. stocks were mixed late Thursday, with the S&P 500 and Nasdaq erasing most of their earlier losses and moving around positive territory late in the session, while the Dow remained lower. Rising Treasury yields continued to pressure small-cap stocks, with the Russell 2000 ETF coming off roughly $3.3 billion in outflows last week, while inflation concerns remained in focus as businesses continued to signal elevated pricing plans.
AI infrastructure stocks faced fresh scrutiny after reports that Oracle issued a force majeure notice tied to Project Jupiter, an AI data center project. The development weighed on Oracle, Blue Owl, and Bloom Energy, while Dell also traded lower, renewing concerns about the timing of planned AI capacity. Oracle has said the project remains on schedule. In a more constructive AI-related development, Akamai announced a seven-year, $11.6 billion agreement with Anthropic that could expand to roughly $20 billion.
Consumer and transportation names were also under pressure. Carnival fell as concerns over higher fuel costs weighed on the cruise operator, while UPS traded lower as well. McDonald’s remained near a four-year low after its CEO said difficult traffic and inflation conditions were not expected to improve, while Stitch Fix fell on its fiscal 2027 forecast. Elsewhere, Alkami extended its decline after concluding a strategic review and deciding to remain an independent public company, while Kinross Gold fell after cutting its 2026 and 2027 production outlook. Featured: Today's stock pick is on me (Ad) 
| Healthcare | |
Shares of telehealth platform and direct-to-consumer (D2C) personal care products provider Hims & Hers Health (NYSE: HIMS) fell 6.7% on Wednesday, Sept. 23, as investors continue to weigh the fallout from August’s disappointing earnings report and mounting legal pressure, including a securities... Read the Full Story |
| | Industrials | |
Paychex’s (NASDAQ: PAYX) September stock price decline presents a key opportunity for investors, mainly due to the underlying cause. The cause is the Q1 fiscal year 2027 results, which weren’t bad, just not better than expected. The market gets the Paychex AI vulnerability wrong: slow adoption does... Read the Full Story |
| Consumer Staples | |
General Mills (NYSE: GIS) is working on a turnaround and nearing its inflection point. Its Q1 results for fiscal year 2027 (FY2027) were lackluster, but investors must remember this was against tough comp, with a significant divestiture in the numbers.
General Mills sold its yogurt business to foc... Read the Full Story |
| From Our Partners | | Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal.
Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty.
Dylan believes shares could react by December 8th. | | Claim this free stock pick before the December 8 deadline today |
| Technology | |
Sandisk Corporation (NASDAQ: SNDK) crossing the $1,800 threshold represents a shift in how the broader market values memory hardware. For decades, storage was a cyclical, commoditized component tied to personal computer upgrades and consumer electronics. That model is breaking down.
Driven by hyper... Read the Full Story |
| Technology | |
Palantir Technologies (NASDAQ: PLTR) recently received two fresh $250 price targets. It also has one famous short seller who thinks the stock is worth less than $1. Both camps are reading the same second-quarter report. They just reach opposite conclusions.
UBS analyst Karl Keirstead lifted his Pal... Read the Full Story |
| From Our Partners | | Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years. | | Get the seven high-yield dividend stocks free now |
| Consumer Discretionary | |
The National Restaurant Association released optimistic data on Sept. 16, showing total eating and drinking place sales rose 1.2% in August after a modest gain in July.
For many restaurants, the data is a relief after months of rising commodity costs and declining consumer sentiment. But the data a... Read the Full Story |
| Communication Services | |
Shares of Meta Platforms (NASDAQ: META) have been on an absolute tear. The stock’s closing low in August was approximately $543. Since then, shares have gained over 25%.
The company’s Muse personal AI agent has been a primary driver of this surge. Muse recently became the most-downloaded free app ... Read the Full Story |
| Industrials | |
High short interest stocks draw attention for a simple reason. They show where Wall Street's skepticism is concentrated. Short interest measures the percentage of a company's float that has been sold short. When that number climbs, it means a meaningful group of investors expects the stock to fall.... Read the Full Story |
| Energy | |
The primary bottleneck confronting artificial intelligence (AI) is no longer access to advanced semiconductor chips, but access to electricity.
High-density data centers require constant baseload electricity to operate advanced computing clusters, yet traditional public utility connections can take... Read the Full Story |
| Markets | |
While the recent surge in bond rates could spell trouble for some corners of the equities market, there is a silver lining for income investors looking to bolster their dividend portfolios.
As bond yields rise, income distributions from bond exchange-traded funds (ETFs) gradually adjust to reflect ... Read the Full Story |
| Friday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Wednesday, November 04, 2026 at 6:25 PM.
AbbVie Bull Case -
AbbVie recently secured global rights to Nxera Pharma's experimental oral IBD candidate, NXE0033744, in a deal worth up to $1.47 billion including upfront payments and milestones, which diversifies the company's growth pipeline beyond its current immunology and oncology franchises.
-
The company is investing more than £120 million to expand its Oxford R&D facility, signaling a long-term commitment to advancing research in immunology, neurology, and oncology, which supports future product innovation and market expansion.
-
AbbVie reported strong third-quarter earnings with EPS of $3.82, beating analyst estimates of $3.73, and revenue of $17.40 billion, which was also above the consensus of $17.32 billion, demonstrating robust operational performance and demand for its key products like Skyrizi and Rinvoq.
-
Wall Street sentiment has improved significantly, with multiple brokerages including Morgan Stanley and Piper Sandler raising their price targets, and the stock currently trading at $294.15, which is near its 52-week high of $298.74, reflecting strong investor confidence in the company's trajectory.
-
AbbVie recently increased its quarterly dividend to $1.82 per share, representing a 5.2% increase from the previous $1.73, which provides a growing income stream for investors and signals management's confidence in the company's cash flow generation.
AbbVie Bear Case -
AbbVie discontinued a Phase 2 solid-tumor drug program due to "limited benefit," which is a setback for its oncology pipeline and may raise concerns about the success rate of its other experimental cancer treatments.
-
The company's valuation may be stretched after its recent rally, with a P/E ratio of 50.63, which is high compared to many peers, potentially limiting further upside if growth expectations are not met in the coming quarters.
-
AbbVie's payout ratio is currently 119.10%, meaning the company is paying out more in dividends than it is earning in net income, which could be a concern for long-term sustainability of the dividend if earnings do not grow sufficiently.
-
Insider selling has been notable, with EVP Nicholas Donoghoe selling 32,710 shares in August 2026, representing a 30.53% decrease in his position, which some investors may interpret as a lack of confidence in the stock's near-term performance.
-
Short interest has been relatively high, with 15.58 million shares shorted as of October 2026, which is a significant portion of the float and could indicate that some investors are betting against the stock's future performance.
| | View Today's Stock Pick |
|
| |
|
|
